Clinical Scorecard: Epigenetic Markers May Predict Glaucoma Progression
At a Glance
| Category | Detail |
|---|---|
| Condition | Primary Open-Angle Glaucoma (POAG) |
| Key Mechanisms | Epigenetic age acceleration linked to disease progression via DNA methylation patterns. |
| Target Population | Patients with Primary Open-Angle Glaucoma (POAG) |
| Care Setting | Ophthalmology clinics and research settings |
Key Highlights
- Significant association between epigenetic age acceleration and glaucoma progression.
- Fast progressors showed greater epigenetic aging than slow progressors.
- Epigenetic age calculated using clocks like Horvath and Hannum.
- Age acceleration may indicate susceptibility beyond traditional IOP-related damage.
- Potential for predictive models incorporating epigenetic age in clinical practice.
Guideline-Based Recommendations
Diagnosis
- Assess epigenetic age using DNA methylation profiles in POAG patients.
Management
- Consider therapies aimed at slowing aging or enhancing mitochondrial function.
Monitoring & Follow-up
- Utilize epigenetic aging metrics for monitoring disease progression.
Risks
- Increased odds of fast progression with each additional year of epigenetic age.
Patient & Prescribing Data
200 POAG patients, divided into fast and slow progressors.
Accelerated biological aging may contribute to optic nerve susceptibility.
Clinical Best Practices
- Incorporate epigenetic aging metrics into predictive models for glaucoma.
- Conduct prospective validation of findings in clinical settings.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.